ERBB2 and cancer: Recent progress in the development of molecular cancer therapy has revealed new molecular-targeting drugs, such as EGFR-targeting drug ZD1839 (Iressa) and HER2-targeting anti-HER2 monoclonal antibody trastuzumab (Herceptin), to be potent therapies for specific cancers [32-34].